Secondary analysis suggests DED severity, systemic medication use correlation

News
Article

The analysis, which pulled data from the DRy Eye Assessment and Management (DREAM) study, found that users of corticosteroids had multiple worse and consistent DED signs.

Closeup of red and irritated eye Image Credit: AdobeStock/KryuchkaYaroslav

Image Credit: AdobeStock/KryuchkaYaroslav

A secondary analysis drawn from data collected from the DRy Eye Assessment and Management (DREAM) Study found an association between systemic medication use and an increase in severity of dry eye disease (DED). Of the medications evaluated, worse DED signs and symptoms were found in corticosteroid, antihistamines, aspirin, vitamin D3, and medications for seizure users compared to non-users, of which users of corticosteroids had multiple worse and more consistent DED signs.1

The DREAM study was initially published in 2018 and was a multi-center, double-masked, placebo-controlled, randomized clinical trial that assessed the efficacy and safety of oral ω-3 supplementation for the treatment of DED. The study consisted of 535 participants with symptoms and sign of moderate to severe DED who treated with 3000 mg ω-3 (2000 mg eicosapentaenoic acid and 1000 mg docosahexaenoic acid) per day or placebo (5000 mg olive oil per day). Participants were assessed for DED signs using tear breakup time, Schirmer testing, corneal fluorescein staining, conjunctival lissamine green staining, meibomian gland dysfunction, and tear osmolarity. DED symptoms were assessed using the ocular surface disease index. At the conclusion of the study, no evidence was found to indicate a beneficial effect of ω-3 supplements regarding DED.2

The secondary analysis, published in a paper in The Ocular Surface, categorized participant-reported systemic medications into antidepressants, antihistamines, aspirin, corticosteroids, diuretics, nonsteroidal anti-inflammatory drugs, proton pump inhibitors, statins, vitamin D3, and medications for diabetes mellitus, hypertension, hypothyroidism, migraine, and seizure.1

The analysis found that antihistamine, vitamin D3, aspirin, and corticosteroid users had a lower tear break-up time. Antihistamine and corticosteroid users had higher OSDI scores. Corticosteroid and seizure medication users had higher composite severity scores. Vitamin D3 users had greater meibomian gland dysfunction, while diuretic users had less. Additionally, corticosteroid users had lower Schirmer test scores, and higher cornea fluorescein staining.1

References:
  1. Guo M. Diaz GM. Yu Y. et al. Association between systemic medication use and severity of dry eye signs and symptoms in the Dry eye assessment and management (DREAM) study. The Ocul Surf. Online March 2024. April 2024;32:112-119. https://doi.org/10.1016/j.jtos.2024.01.009
  2. Asbell PA. Maguire MG. Peskin E. et al. N-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease. The New Eng Jour of Med. April 2018;378(18):1681-1690. doi:10.1056/NEJMoa1709691
Recent Videos
Walline, OD, PhD, FAAO, outlines how to predict myopia progression and delay its onset in an exclusive interview with Optometry Times.
Jeffrey Walline, OD, PhD, FAAO, overviews a presentation he gave on the Bifocal Lenses in Nearsighted Kids 2 (BLINK2) cohort study at the Collaborative Community on Ophthalmic Innovation (CCOI).
Walline, OD, PhD, FAAO, states that the best way to learn the benefits of artificial intelligence for your practice is to stay on top of continuing education attendance.
Abby Gillogly Harsch, OD, FAAO, FSLS, shares a specific complex case of scleral lens fitting that she presented on at this year's GSLS.
Katie Rachon, OD, FAAO, Dipl ABO, shares her excitement for the upcoming conference and what it means for an optometrist's toolbox.
From contact lens dropout to addressing diabetic retinopathy in rural communities, optometrists choose an area of eye care research that they would expand, given the appropriate resources.
From new treatments on the horizon for macular degeneration to strengthening comanagement ties, optometrists cite a lot to be excited about in the coming year.
Practice owners testify to the importance of trying new things, not being afraid to fail, and utilizing community as a resource when starting up a new practice.
Optometrists reflect on their residency experiences and provide advice to current residents.
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
© 2025 MJH Life Sciences

All rights reserved.